Wed, Jul 30, 2014, 2:25 PM EDT - U.S. Markets close in 1 hr 35 mins


% | $
Click the to save as a favorite.

Supernus Pharmaceuticals, Inc. (SUPN) Message Board

  • pharmaherobw pharmaherobw Nov 14, 2012 4:53 PM Flag



    Rockville-based Supernus Pharmaceuticals Inc., which raised $50 million in an initial public offering in May, is going back to the market with a secondary stock offering.

    In a regulatory filing, Supernus says it plans to raise as much as $86.25 million. It did not set a per share price or a date for the offering.

    Supernus received tentative Food and Drug Administration approval for one of its lead epilepsy drugs in June. It says proceeds from the secondary offering will be used to fund its commercial launch, as well as pay down debt and fund ongoing clinical trials.

    The offering will significantly increase its shares outstanding. Based on Supernus' Tuesday closing price, it would add 6.8 million shares to the 24.5 million shares the company currently has.

    Supernus stock (NASDAQ: SUPN) fell 77 cents to $11.88 in Wednesday trading.

    Supernus posted a third-quarter net loss of $13.5 million, compared to a net loss of $10.6 million a year earlier.

    Sentiment: Strong Sell

    This topic is deleted.

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.